MedTrace Logo

Low- and Moderate-intensity Statin and Clinical Outcome of Primary Prevention in Individuals Aged >70 Years: the SCOPE-70 RCT Study

NCT03770312 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 724

Last updated 2025-11-18

No results posted yet for this study

Summary

One of the most effective drug in the primary prevention of cardiovascular disease is statins. The protective effects of statin on developement of cardiovascular disease has been demonstrated in elderly individuals. Since side effects of statin are more common in elderly individuals than in younger individuals, clinical guidelines recommend that use of low intensity statin is considered in elderly individuals. However, there are few randomized clinical trials evaluating the safety and efficacy of different intensity statins in elderly individuals.

This is a multicenter, prospective, randomized clinical trial to compare efficacy and safety between low and high intensity statin for primary prevention of cardiovacsular disease in elderly individuals.

Conditions

  • Healthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular Disease

Interventions

DRUG

Low intensity statin

Use of low intensity statin for primary prevention of cardiovascular disease.

DRUG

Moderate intensity statin

Use of moderate intensity statin for primary prevention of cardiovascular disease.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-05
Primary Completion
2026-01-16
Completion
2026-01-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03770312 on ClinicalTrials.gov